Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 71

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 1
Chunk 71
---
 Listing Rule 5810(c)(3)(A).
If at any time prior to June 23, 2025, the bid price of the Company’s common stock closes at $1.00 per share or more for a minimum
of 10 consecutive trading days, the Company will regain compliance with the Minimum Bid Price Requirement.

Effective as of the close
of business on June 6, 2025 with an effective trading date of June 9, 2025 the Company effectuated a 1-for-8 reverse split to attempt
to maintain compliance with the $1.00 minimum bid requirement and to avoid, or at least mitigate, the likely adverse consequences of our
common stock being delisted from the Nasdaq Capital Market by producing the immediate effect of increasing the bid price of our common
stock.

On June 24, 2025, the Company
received notification that they had regained compliance with the Minimum Bid Price Requirement.

There can be no assurance,
however, that we will be able to continue to maintain compliance with the continued listing requirements for the Nasdaq Capital Market
and our common stock could be delisted in the future. In addition, we may be unable to meet other applicable listing requirements of the
Nasdaq Capital Market, including maintaining minimum levels of stockholders’ equity or market values of our common stock in which
case, our common stock could be delisted notwithstanding our ability to demonstrate compliance with the Minimum Bid Price Requirement.

Delisting from the Nasdaq
Capital Market may adversely affect our ability to raise additional financing through the public or private sale of equity securities,
may significantly affect the ability of investors to trade our securities and may negatively affect the value and liquidity of our common
stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional
investors or interest in business development opportunities.

Historically we have not paid dividends
on our common stock, and we do not anticipate paying any cash dividends in the foreseeable future.

We have never paid cash dividends
on our common stock. We intend to retain our future earnings, if any, to fund operational and capital expenditure needs of our business,
and do not anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, of our common stock
will be the sole source of gain for our common stockholders in the foreseeable future.

Our stock price is speculative, and there
is a risk of litigation.

The trading price of our common
stock has in